Welcome to our dedicated page for ZEVRA THERAPEUTICS SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zevra Therapeutics filings document the regulatory record of a Nasdaq-listed, Delaware commercial-stage rare-disease therapeutics company. Recent Form 8-K reports furnish quarterly financial results and corporate updates, record leadership and principal financial officer changes, and disclose compensatory arrangements and inducement awards tied to executive appointments.
The filing record also includes definitive proxy materials covering board matters, executive compensation and shareholder voting items. Material-event filings describe the completed transfer of Zevra's SDX portfolio, including AZSTARYS and KP1077, under an asset purchase and settlement agreement, while Exchange Act disclosures identify the company's common stock on the Nasdaq Global Select Market.
Zevra Therapeutics, Inc. reported a leadership change in its finance organization. The board appointed Timothy Sangiovanni, currently Senior Vice President, Finance and Corporate Controller and principal accounting officer, to serve as interim principal financial officer effective January 1, 2026. He has held senior finance and reporting roles at the company since 2015. The company noted that there was no change to Mr. Sangiovanni’s compensation arrangements in connection with this interim appointment.
Zevra Therapeutics, Inc. director Alicia Secor has filed an initial insider ownership report indicating that she does not beneficially own any of the company’s securities. The filing is made as a Form filed by one reporting person in her capacity as a director of Zevra Therapeutics.
The event date for this disclosure is 12/02/2025, and the form is signed by an attorney-in-fact on her behalf. The remarks section explicitly states that no securities are beneficially owned, meaning there are currently no reported direct or indirect holdings by this director.
Zevra Therapeutics, Inc. reported that its Chief Financial Officer, Treasurer, and principal financial officer, R. LaDuane Clifton, has decided to resign effective December 31, 2025 to pursue other professional opportunities. The company and Mr. Clifton entered into a Separation Agreement under which he will receive separation benefits after his departure, including cash payments equal to 12 months of his annual base salary, an annual bonus equal to 40% of his base salary, up to 12 months of company-paid COBRA continuation coverage, and full vesting of his outstanding equity awards. These benefits are conditioned on his continued compliance with non-disparagement, confidentiality, non-competition, and non-solicitation covenants. Zevra has begun a search process to identify a new chief financial officer and issued a press release describing these matters.
Zevra Therapeutics (ZVRA) reported sharply improved results in its Q3 2025 10-Q. Revenue rose to $26.1 million from $3.7 million a year ago, driven mainly by MIPLYFFA sales. The company posted a small net loss of $0.5 million for the quarter versus a $33.2 million loss last year.
For the nine months ended September 30, 2025, revenue reached $72.3 million, and net income was $71.1 million, aided by a $148.3 million gain from selling a priority review voucher. Results also reflect a $58.7 million intangible asset impairment and $11.7 million in inventory write-downs. MIPLYFFA generated $22.4 million in Q3 and $61.0 million year-to-date; OLPRUVA contributed $0.1 million in Q3 and $0.5 million year-to-date. The AZSTARYS license produced $1.2 million in Q3.
Liquidity strengthened: cash and cash equivalents were $54.4 million with $175.9 million in investment securities at fair value, and stockholders’ equity increased to $133.2 million. Long-term debt stood at $61.3 million under the 2024 term loan facility. As of November 3, 2025, 56,297,535 shares of common stock were outstanding.
Zevra Therapeutics (ZVRA) reported it has furnished a press release announcing financial results and corporate updates for the third quarter ended September 30, 2025. The company also scheduled a conference call and audio webcast for November 5, 2025 at 4:30 p.m. ET to discuss these updates.
The press release is furnished as Exhibit 99.1 and, as stated, is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings except as expressly specified.
Neil F. McFarlane, President and CEO of Zevra Therapeutics, Inc. (ZVRA), reported equity transactions on 10/10/2025. He received 50,000 restricted stock units (RSUs) that vested and settled under the company plan, bringing his direct holding to 241,516 shares. On the same date he sold 19,500 shares at a price of $10.8158, leaving him with 222,016 shares. The RSUs were part of an inducement award where 25% vested and settled on 10/10/2024 and another 25% on 10/10/2025, with the remaining 50% vesting in equal annual installments thereafter subject to continued employment; full vesting also occurs on a change of control or certain termination events. The sale was made pursuant to a 10b5-1(c) plan adopted 03/21/2025.
ZEVRA THERAPEUTICS, INC. (ZVRA) filed a Form 144 disclosing a proposed sale of 19,500 common shares by an insider through Morgan Stanley Smith Barney LLC on 10/10/2025. The filing lists an aggregate market value of $210,990 and shows 56,135,091 shares outstanding, implying the sale represents a small fraction of total shares.
The securities were acquired as Restricted Stock Units and the acquisition and planned sale date are both reported as 10/10/2025. No other sales in the prior three months are reported, and the filer affirms they are not in possession of undisclosed material adverse information.
Tamara A. Favorito, a director of ZEVRA THERAPEUTICS, INC. (ZVRA), purchased 3,175 shares of the company's common stock on 09/12/2025 at a reported price of $7.7852 per share. After the transaction, Ms. Favorito beneficially owned 3,894 shares. The Form 4 was executed by Timothy J. Sangiovanni as attorney-in-fact and dated 09/16/2025.
Alvin Shih, a director of Zevra Therapeutics (ZVRA), purchased 20,000 shares of the company's common stock on 09/12/2025 at a weighted-average price of $7.89 per share. The Form 4 shows the transaction was reported as an acquisition and that the reporting person beneficially owns 20,000 shares following the purchase. The footnote states the $7.89 figure is a weighted average from multiple trades priced between $7.85 and $7.90 and that detailed allocation of trades is available on request. The filing was signed by an attorney-in-fact on behalf of Mr. Shih.
Zevra Therapeutics director John B. Bode acquired 5,000 shares of the company's common stock on 08/19/2025 at a reported price of $9.165 per share. After the purchase he beneficially owns 45,000 shares. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 08/20/2025.